Global Dry Powder Inhalers Market - 2022-2029

Global Dry Powder Inhalers Market - 2022-2029

Market Overview

The global dry powder inhalers market size was valued US$937 million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 5.1% during the forecast period (2022-2029).

Dry powder inhalers (DPI) deliver drugs in the form of dry powder to the lungs of patients suffering from respiratory disorders. These are preferred over pressurized metered dose inhalers due to rising environmental concerns regarding chloro-flouro carbon (CFC) used as a propellant in P-MDIs.

Market Dynamics

The global dry powder inhalers market is due to an increasing demand of dry powder inhalers owing to the rise in incidence and prevalence of asthma and COPD, technological advancements, and a growing geriatric population.

Technological advancements in novel drugs drives the growth of the market

Technological advancements are anticipated to drive the growth of the market in the forecast period. Limitations of traditional treatments, such as the late onset of action and low efficacy, are projected to encourage the development of novel targeted drugs, thereby driving the market. For instance, in February 2021, Sanofi, in collaboration with Regeneron Pharmaceuticals, initiated a Phase III clinical trial to assess the efficacy and safety of itepekimab on the annualized rate of acute moderate-or-severe COPD exacerbations in former smokers with moderate-to-severe chronic obstructive pulmonary disease (COPD). The trial is expected to be completed in July 2024. The market players are adopting various strategies such as product launches, developments, collaborations, acquisitions, and expansions to increase their market shares. For instance, In July 2020, Lonza launched a Center of Excellence for Dry Powder Inhaler (DPI) drug product development at its exsiting facility in Bend, OR, in which the company will use its expertise in particle engineering to help customers to create and evaluate formulations.

According to the World Health Organization (WHO) 2021 factsheet, COPD is the third-leading cause of death worldwide, causing 3.23 million deaths in 2019. Over 80% of these deaths occurred in low- and middle-income countries (LMIC). Moreover, the increasing geriatric population globally is boosting the market growth.

The high cost of asthma treatment is expected to hamper the market growth

The expensive cost of asthma inhalers could limit industry expansion. A growing proportion of patients undergoing respiratory operations need innovative inhalers because they have chronic and respiratory disorders like asthma and COPD. However, the adoption rate of inhalers may decline throughout low-income countries as a result of the high cost of these devices for these disorders. For instance, according to the TalktoMira, Inc, the average price of one brand-name asthma inhaler is $292.91 without insurance.

The expensive price of these gadgets and necessary accessories could limit market expansion. Market growth in underdeveloped nations with relatively low-income levels may be constrained because to the high costs involved with asthma procedures. As a result, it might be challenging for middle-income and low-income countries to adopt such expensive devices. Therefore, the high price of these advanced devices could restrain the expansion of the inhalers market over the estimated year.

COVID-19 Impact Analysis

COVID-19 impacted the global supply chain of pharmaceuticals, affecting the Asthma and COPD drug market. According to a research study by José Luis Izquierdo et al., published in the European Respiratory Journal, March 2021, allergy-related factors such as rhinitis and eczema were less common in asthmatic patients with COVID-19. There was a high prevalence of these comorbidities observed in patients with COVID-19 who required hospital admission.

Furthermore, the use of inhaled corticosteroids (ICS) was lower in patients who required hospitalization due to COVID-19 compared to non-hospitalized patients (48.3% versus 61.5%). Although patients treated with biologics showed increased severity and more comorbidities at the ear, nose, and throat levels, COVID-19-related hospitalizations in these patients were relatively low (0.23%). Thus, patients with asthma and COVID-19 were older and at increased risk due to comorbidity-related factors. Inhaled corticosteroids (ICS) and biologics are generally safe and may be associated with a protective effect against severe COVID-19 infection. Chronic obstructive pulmonary disease (COPD) patients have an increased risk of severe pneumonia and poor outcomes when they develop COVID-19. This may be related to poor underlying lung reserves or increased expression of ACE-2 receptors in small airways.

Industry Analysis

The global dry powder inhalers market provides in-depth analysis of the market based on various industry factors such as porter’s five forces, regulatory analysis, supply chain analysis and pricing analysis, reimbursement policies, technological advancements, PEST analysis.

Segment Analysis

The capsule based devices segment is expected to hold the largest market share in global dry powder inhalers market

The capsule based devices segment is expected to dominate the global dry powder inhalers market, owing to increase in number of manufacturers offering diverse products in the segment and rise in adoption and preference of health care providers and patients for these devices and also increase in prevalence and incidence of asthma. For instance, In May 2019, Capsugel Zephyr is launched by Lonza, a dry-powder inhalation capsule portfolio that is optimized to provide superior performance and compatibility between the capsule/device and capsule/formulation.

The substantial increase in prevalence and incidence of asthma has led to an increase in the patient population, which has, in turn, increased the demand for these devices. According to the World Health Organization (WHO) 2021 factsheet, asthma is a major non-communicable disease (NCD), affecting both children and adults. Globally, it affected an estimated 262 million people in 2019 and caused 461,000 deaths. Enormous investments in the study of asthma drugs accompanied by strategic collaborations such as mergers and acquisitions are the business strategies followed by the major companies in the market. For instance, in October 2019, the US Food and Drug Administration (FDA) approved the self-administration of AstraZeneca’s asthma drug Fasenra, a pre-filled, single-use auto-injector.

Geographical Analysis

North America region holds the largest market share in the global dry powder inhalers market

North America dominates the market for dry powder inhalers and is expected to show a similar trend over the forecast period, owing to the rising incidence of diseases such as COPD and asthma, the aging population, increasing research and development activities, and the presence of key market players.

In the United States, asthma is more common in adult women than adult men. According to the Centers for Disease Control and Prevention 2020 report, in the United States, approximately 25 million Americans have asthma. This equals to about 1 in 13 Americans, including 8% of adults and 7% of children. About 20 million US adults aged 18 years and over have asthma. Similarly, asthma is a major public health concern in Canada. As a lifelong respiratory illness, asthma affects the work productivity, quality of life, mental health, and psychological well-being of the Canadian population. In Canada, over 3.8 million individuals had asthma in 2019, as per Canada's 2019 annual asthma survey report. The high number of patients affected by asthma increases the demand for drugs for the treatment of the target disease, thereby boosting the growth of this region.

Competitive Landscape

The dry powder inhalers market is highly competitive, owing to big market players in the industry. The key dry powder inhalers players which are contributing to the growth of the global market include AstraZeneca PLC, Boehringer Ingelheim GmbH, Vectura Group plc, Otsuka Pharmaceutical Co. Ltd, Norton Healthcare, Respira Therapeutics, Inc, Chiesi, Cipla and among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market globally. For instance, in March 2021, Glenmark Pharmaceuticals Ltd, launched a bioequivalent version of Tiotropium Bromide dry powder inhaler (DPI) under the brand name - Tiogiva, in UK for the treatment of chronic obstructive pulmonary disease (COPD).

Key Companies to Watch

Vectura Group PLC:

Overview: Vectura Group PLC develops inhaled therapies for the treatment of respiratory diseases. The Company's main products are used to treat asthma and chronic obstructive pulmonary disease. Vectura also develops products for lung pathologies and non-respiratory.

Vectura has ten key inhaled and eleven non-inhaled products marketed by partners with global royalty streams, and a diverse partnered portfolio of drugs in clinical development.

Product Portfolio: Gyrohaler: is a multi-unit dose dry powder inhaler designed to deliver locally acting drugs to the lungs.

Key Developments: In 2021, Vectura expands dry powder inhaler development and manufacturing capabilities at its facility in chippenham, U.K.

The global dry powder inhalers market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.